apremilast / Generic mfg. - LARVOL DELTA

Recalcitrant Erythema Multiforme Minor Successfully Treated With Apremilast-A Novel Insight. (PubMed, Australas J Dermatol) - No abstract available

Journal • Dermatology

Quantifying the Role of Specialty Medications in Medicare Part D Expenditures in Dermatology. (PubMed, JAMA Dermatol) - "New therapies approved after 2013 (Otezla, Cosentyx, Taltz, Dupixent, Tremfya, Skyrizi, and Odomzo) accounted for 69.5% of all spending growth. Prescription rates increased more slowly for older specialty drugs (Humira, Enbrel, Stelara, and Erivedge), but their prices increased more (9.2% annually) than prices for newer agents...While the price of the average dermatologic medication has increased rapidly, this primarily reflects increased prescribing of newly introduced specialty drugs. While these therapies expand treatment options, their rising share of costs highlights the need for policies that balance innovation, access, and affordability."

Journal • Medicare • Reimbursement • US reimbursement • Dermatology

Patient with neuropathic ulcers and morphea treated with apremilast. (PubMed, Actas Dermosifiliogr) - No abstract available

Journal

A case of eosinophilic pustular folliculitis involving palmoplantar successfully treated by apremilast. (PubMed, Skin Health Dis) - "We presented a man with EPF involving the face, palms and soles, successfully treated by apremilast, a phosphodiesterase-4 inhibitor. Apremilast's efficacy in this case adds to emerging evidence supporting its use in EPF, particularly when traditional treatments fail."

Journal • Dermatology • Inflammation

Oral and topical vitamin D treatment strategies in psoriasis. (PubMed, Skin Health Dis) - "Moreover, combination therapy with immunomodulators such as apremilast and methotrexate has shown promise as well. Further study combining vitamin D supplementation with pre-existing treatments may also augment the effect of monotherapy. Studies on the synergistic effects of combination therapies with oral vitamin D or the development of foam-based or microneedle drug delivery systems may be promising next steps."

Journal • Review • Dermatology • Immunology • Psoriasis

Apremilast Shows Long-Term Benefit in Early Oligoarticular Psoriatic Arthritis (HCPLive) - P4 | N=310 | FOREMOST (NCT03747939) | Sponsor: Amgen | "The FOREMOST trial showed large reductions in swollen joint count (SJC) and tender joint count (TJC) among patients with oligoarticular (oligo) psoriatic arthritis (PsA) taking apremilast vs placebo at week 16. Patients had sustained reductions through week 48, demonstrating the benefit of apremilast. The research was presented at the 2025 Society of Dermatology Physician Assistant (SDPA) annual summer meeting from June 25 – 29th in Washington, DC...A subgroup analysis examined the outcomes by baseline body mass index (BMI): < 25, 25 to < 30, and ≥ 30 kg/m2...Compared with placebo at baseline (n = 62), the apremilast arm (n = 126) had a mean BMI of 30 kg/m2 (vs 31 kg/m2), a mean SJC of 1.5 (vs 1.2), a mean TJC of 1.9 (vs 1.8), mean active joint count of 2.1 (vs 1.9), and a mean HAQ-DI of 1.26 (vs 1.24)....Participants on apremilast had greater reductions in SJC and TJC by week 16 compared with placebo."

P4 data • Psoriatic Arthritis

A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis (clinicaltrials.gov) - P3 | N=48 | Recruiting | Sponsor: Amgen | Trial completion date: Dec 2032 ➔ Mar 2036 | Trial primary completion date: Dec 2032 ➔ Mar 2036

Trial completion date • Trial primary completion date • Idiopathic Arthritis • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rare Diseases • Rheumatology • Seronegative Spondyloarthropathies

Psoriasis. (PubMed, Nat Rev Dis Primers) - "In moderate-to-severe disease, oral systemic therapies, such as methotrexate, ciclosporin, acitretin, apremilast and deucravacitinib, provide a range of immunomodulatory effects. Early screening for psoriatic arthritis, proactive cardiovascular risk reduction and multidisciplinary care are crucial to optimizing long-term outcomes. Ongoing research continues to advance precision medicine approaches, with the goal of enhancing treatment durability and improving quality of life for individuals living with psoriasis."

Journal • Review • Cardiovascular • CNS Disorders • Dermatology • Immunology • Inflammation • Inflammatory Arthritis • Mental Retardation • Metabolic Disorders • Psoriasis • Psoriatic Arthritis • Psychiatry • Rheumatology • Seronegative Spondyloarthropathies • HLA-C • IL12A • IL12B • IL17A • IL17RA • IL23A • TYK2

Dramatic clearance of extensive psoriasis in a pediatric patient with upadacitinib (CDA 2025) - "Introduction : Psoriasis is a chronic inflammatory skin condition that commonly presents on the knees, elbows, trunk, and scalp, but can involve the palmoplantar surfaces. The patient presented with severe palmoplantar psoriasis at age 3, progressing to widespread disease by age 8, with genital involvement, painful fissures, and impaired mobility. He underwent extensive treatments, including methotrexate, acitretin, cyclosporine, ustekinumab, ixekizumab, apremilast, secukinumab, and deucravacitinib, alongside topical therapies including clobetasol, roflumilast, halobetasol and betamethasone diproprionate-based preparations. Despite moderate responses to some regimens, sustained control was not achieved, and treatment side effects, including elevated liver enzymes, dyslipidemia and gastrointestinal discomfort, further limited options."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Dyslipidemia • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Metabolic Disorders • Pain • Pediatrics • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Psoriasis: an update on topical and systemic therapies. (PubMed, Aust Prescr) - "Newer systemic therapies, including oral medicines and injectable biologics, can only be used following unsuccessful treatment with traditional therapies such as methotrexate and phototherapy. Biologic therapies for psoriasis offer the possibility of near-complete symptom resolution in people with psoriatic disease."

Journal • Review • Cardiovascular • CNS Disorders • Depression • Dermatology • Immunology • Inflammation • Psoriasis • Psychiatry • Rheumatology

Balancing efficacy and hepatotoxicity: a comprehensive review of oral medications in psoriasis management. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Oral systemic therapies, including methotrexate, cyclosporine, acitretin, and apremilast, remain integral to psoriasis management, particularly for patients with moderate-to-severe disease who cannot afford biologic therapy. A balanced approach that integrates clinical monitoring, lifestyle modifications, and emerging precision medicine techniques is essential for optimizing long-term treatment outcomes. Future research should focus on refining predictive models for drug-induced liver injury and developing targeted therapies with improved efficacy and safety profiles."

Journal • Review • Dermatology • Hepatology • Immunology • Inflammation • Liver Failure • Psoriasis • TYK2

A phase IIb single-center study to assess the efficacy of apremilast for the treatment of nummular eczema. (PubMed, J Dtsch Dermatol Ges) - "Phosphodiesterase-4 inhibition by apremilast showed no beneficial effects for the treatment of NE."

Clinical • Journal • P2b data • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology

Understanding the Phenotypic Switch Between Psoriasis and Atopic Dermatitis (CDA 2025) - "When looking at dupilumab for the treatment of AD, eczema, or dermatitis, a signal emerges for psoriasiform dermatitis (Reporting Odds Ratio [95% Confidence Interval] =3.23 [1.69,1.35]) as an adverse event (AE), but not psoriasis (3.23 [1.69,1.35])...Limiting the indication to PsO strengthened signals for psoriasiform dermatitis ( TNF - α =3.01 [4.26,2.13] and IL-17 inhibitors=11.46 [14.34,9.16]), and allowed new ones to emerge for psoriasiform dermatitis (IL-23 inhibitors=2.49 [4.80,1.29] and apremilast=2.04 [3.71,1.13]), eczema (IL-17 inhibitors=1.84 [2.06,1.64]), and dermatitis (IL-17 inhibitors=1.95 [2.29,1.66]), but not AD... Taken together, our study proposes a comprehensive model for the phenotypic switch between atopic dermatitis and psoriasis. This study is the first of its kind, and it has major implications for dermatologic prescribing practices."

Asthma • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis • Respiratory Diseases • IL12A • IL17A • IL23A

ONWARD2: A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (clinicaltrials.gov) - P3 | N=840 | Active, not recruiting | Sponsor: Alumis Inc | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2026 ➔ Dec 2025 | Trial primary completion date: May 2026 ➔ Sep 2025

Enrollment closed • Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis

ONWARD1: A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P3 | N=840 | Active, not recruiting | Sponsor: Alumis Inc | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2026 ➔ Dec 2025 | Trial primary completion date: May 2026 ➔ Sep 2025

Enrollment closed • Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis

BEAN: Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease (clinicaltrials.gov) - P3 | N=60 | Recruiting | Sponsor: Amgen | Trial completion date: Jul 2028 ➔ Dec 2030 | Trial primary completion date: Aug 2027 ➔ Feb 2030

Trial completion date • Trial primary completion date • Immunology • Pediatrics • Rare Diseases

Dose-response Study of Apremilast in Women and Men With Alcohol Use Disorder (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Yale University

New P2 trial • Addiction (Opioid and Alcohol)

Lupus miliaris disseminatus faciei: A rare facial granulomatous disorder (CDA 2025) - "Variable improvement has been reported with systemic steroids, isotretinoin, dapsone, tetracycline or nitroimidazole-based antibiotics, antimalarials, antituberculosis therapy, tranilast, apremilast, tacrolimus, cyclosporine, and JAK inhibitors...Although doxycycline treatment failed, the patient improved with a tapering prednisone course and isotretinoin 60 mg daily...While it often resolves spontaneously, early intervention is crucial to minimize cosmetic and psychological impacts. The variable efficacy of treatments highlights the need for tailored therapeutic approaches."

Aesthetic Medicine • Dermatitis • Dermatology • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lupus • Respiratory Diseases • Rosacea • Sarcoidosis • Tuberculosis

Efficacy and Safety of Phosphodiesterase-4 Inhibitors in Vitiligo: A Systematic Review (CDA 2025) - "Oral apremilast was most commonly used (110/114, 96.4%) followed by topical crisaborole (4/114, 3.5%). A MEDLINE, Cochrane, and Embase search was conducted under PRISMA guidelines using the following keywords and variations: “vitiligo” and “PDE4i”. The search yielded 11 studies with 114 participants with a mean age of 38.1 years (range: 16-71 years), consisting of 49% males. Treatments were categorized as PDE4i treatment with concomitant medications (85/114, 74.5%) or PDE4i monotherapy (29/114, 25.4%)."

Clinical • Review • Dermatology • Immunology • Vitiligo

SPANISH COHORT OF PSORIATIC ARTHRTIS PATIENTS TREATED WITH GUSELKUMAB (EULAR 2025) - "All 112 patients were previously treated with conventional systemic disease-modifying antirheumatic drugs (csDMARDs), being methotrexate (81.3%), leflunomide (41.1%) and sulfasalazine (19,6%) the most frequent treatments used respectively. A mean of 1.4 csDMARDs and 3.0 bDMARDs and tsDMARDs were used in these patients, being adalimumab (67.9%), etanercept (23.2%), golimumab (24.1%), infliximab (15.2%), certolizumab (20.5%), secukinumab (48.2%), ixekizumab (32.1%) and ustekinumab (19.2%) the most frequent therapeutic agents used. Regarding tsDMARDs JAK-i and apremilast were used in 23.2% and 20.5% of patients respectively (Figure 1B-C-D)... In this study, we present a cohort of patients from the northern of Spain treated with guselkumab under real-world clinical practice conditions with long-term effectiveness data. The drug showed high persistence (84.31% in the first year) in a more complex patient profile than those examined in clinical trials. There were no notable..."

Clinical • Dermatology • Immunology • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • CRP

Real-World Switching Patterns for Patients with Psoriatic Arthritis on First-Line Advanced Therapies (EULAR 2025) - "Switching was evaluated for the overall population, stratified by the mechanism of action (MOA; reference IL-23i) and individual drugs (reference: risankizumab (RZB))...RZB was associated with significantly lower proportion of switchers (3.8%) than guselkumab (12.9%), followed by secukinumab (18.8%), ixekizumab (20.8%), apremilast (26.9%), etanercept (30.0%) and adalimumab (32.4%) (all P<0.05)... The proportion of PsA patients taking 1LAT who switched over 12 months was the lowest with IL-23i. At the individual drug level, RZB was associated with the lowest odds of switching."

Clinical • Metastases • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A

Combination therapy with two biologic/targeted synthetic DMARDs in 1260 patients with immune mediated inflammatory diseases. A Systematic Literature Review for current landscape in efficacy and safety (EULAR 2025) - "The following categories were reported: TNFi+IL/23i (21 studies/245 patients), TNFi+IL/17i (3 studies/66 patients), JAKi+any b/tsDMARDs (9 studies/55 patients), Vedolizumab+JAKi (6 studies/14 patients), Vedolizumab+TNFi (17 studies/163 patients), Vedolizumab+IL/23i (14 studies/48 patients), Vedolizumab+ IL/17i (1 study/ 2 patients), Vedolizumab+ Ocrelizumab (1 study/1 patient)|, Apremilast+any b/tsDMARDs (14 studies/87 patients), Abatacept+any b/tsDMARDs (3 studies/289 patients), Rituximab+any b/tsDMARDs (5 studies/219 patients), Anakinra or Canakinumab+ any b/tsDMARDs (2 studies/166 patients) IL/17i+IL/23i (2 studies/4patients), TNFi+TNFi (1patient)...This figure appears to be even higher in the combination of vedolizumab with ustekinumab, although more data are needed for c. difficile infections in these patients... There are numerous b/tsDMARDs combinations that offer additional improvement in about half of the treatment refractory patients, across indications,..."

Clinical • Combination therapy • Review • Ankylosing Spondylitis • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Musculoskeletal Diseases • Pediatrics • Psoriasis • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • Ulcerative Colitis

Inhibition of structural damage progression with guselkumab, a selective IL-23i, in participants with active PsA: Results through Week 24 of the phase 3b, randomized, double-blind, placebo-controlled APEX study (EULAR 2025) - P3 | " APEX enrolled biologic-naïve adults with active PsA (≥3 tender and ≥3 swollen joints; C-reactive protein ≥0.3 mg/dL) and ≥2 joints with erosions on radiographs of hands and feet, despite previous non-biologic DMARDs, apremilast, or NSAIDs. APEX is the first study to show significant inhibition of structural damage progression with both dosing regimens (Q4W and Q8W) of GUS, a dual-acting selective IL-23i. The GUS safety profile in these biologic-naïve pts with active PsA is consistent with that previously established for GUS across a broad range of pts with PsA, psoriasis, and/or inflammatory bowel disease [2]."

Clinical • Late-breaking abstract • P3 data • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Pain • Psoriasis • Psoriatic Arthritis • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies • CRP • IL23A

Treatment Algorithm Suggestion for Hailey-Hailey Disease. (PubMed, J Cutan Med Surg) - "Treatments include topical agents (corticosteroids, calcineurin inhibitors, antibiotics, calcitriol) and systemic agents (antibiotics, anticholinergics, retinoids, apremilast, dapsone, immunosuppressants, biologicals, naltrexone, vitamin D), as well as procedural therapy such as carbon dioxide laser, botulinum toxin, dermabrasion, photodynamic therapy, and surgery. This review presents a systematic analysis of the literature with a focus on both established and emerging treatment options for Hailey-Hailey disease with the aim to provide a therapeutic algorithm. The evidence supporting each treatment option will be assessed, emphasizing the strength of the data to guide clinical decision-making."

Journal • Review • Dermatology • Genetic Disorders

DOES DMARDS EXPOSURE AFTER CANCER DIAGNOSIS INCREASE THE RISK OF CANCER RECURRENCE OR DEATH (EULAR 2025) - "After cancer diagnosis, most patients were treated with DMARDs (54% csDMARDs, 60% bDMARDs, and tsDMARDs, including 20% apremilast, 7.5% JAKi)... In our cohort of RA and SpA patients with cancer, DMARD treatment was started before the recommended 60 months after diagnosis and did not increase the risk of cancer recurrence or death. Our findings add to recent reports on the real-world safety of different bDMARDs classes including IL6-inhibitors, IL17-inhibitors, IL23-inhibitors, and CTLA4-analogues."

Ankylosing Spondylitis • Breast Cancer • Immunology • Inflammatory Arthritis • Melanoma • Oncology • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Solid Tumor • Spondylarthritis • IL17A